Market closedNon-fractional
Spruce Biosciences/SPRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Ticker
SPRB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
22
Website
www.sprucebiosciences.com
SPRB Metrics
BasicAdvanced
$22M
Market cap
-
P/E ratio
-$1.15
EPS
2.50
Beta
-
Dividend rate
Price and volume
Market cap
$22M
Beta
2.5
Financial strength
Current ratio
4.668
Quick ratio
4.412
Long term debt to equity
3.409
Total debt to equity
6.232
Interest coverage (TTM)
-114.54%
Management effectiveness
Return on assets (TTM)
-28.36%
Return on equity (TTM)
-53.55%
Valuation
Price to revenue (TTM)
2.195
Price to book
0.34
Price to tangible book (TTM)
0.34
Price to free cash flow (TTM)
-0.61
Growth
Revenue change (TTM)
415.63%
Earnings per share change (TTM)
-37.80%
3-year earnings per share growth (CAGR)
-27.02%
What the Analysts think about SPRB
Analyst Ratings
Majority rating from 7 analysts.
SPRB Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2M
-28.57%
Net income
-$12M
17.17%
Profit margin
-580.00%
64.04%
SPRB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.30
-$0.24
-$0.28
-
Expected
-$0.39
-$0.35
-$0.39
-$0.29
-$0.33
Surprise
-18.44%
-15.09%
-37.85%
-3.21%
-
SPRB News
AllArticlesVideos
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
Accesswire·7 hours ago
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
Accesswire·1 day ago
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Spruce Biosciences stock?
Spruce Biosciences (SPRB) has a market cap of $22M as of July 27, 2024.
What is the P/E ratio for Spruce Biosciences stock?
The price to earnings (P/E) ratio for Spruce Biosciences (SPRB) stock is 0 as of July 27, 2024.
Does Spruce Biosciences stock pay dividends?
No, Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Spruce Biosciences dividend payment date?
Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Spruce Biosciences?
Spruce Biosciences (SPRB) has a beta rating of 2.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Spruce Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.